Treatment Free Remission (TFR) in CML Patients （CML-CP）Study

Not yet recruitingOBSERVATIONAL

Enrollment

203

Participants

Timeline

Start Date

July 31, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2031

Conditions

Chronic Myeloid LeukemiaTreatment-free Remission

Interventions

OTHER

TFR(Treatment-Free Remission)

Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)

All Listed Sponsors

lead

Guangdong Provincial People's Hospital

OTHER

NCT05440747 - Treatment Free Remission (TFR) in CML Patients （CML-CP）Study | Biotech Hunter | Biotech Hunter